BXRX
Baudax Bio, Inc. [BXRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BXRX Stock Summary
Top 10 Correlated ETFs
BXRX
Top 10 Correlated Stocks
BXRX
In the News
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases.
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight, skyrocketing into triple-digit percentage gains. The pharmaceutical company — which focuses on innovative products for acute care — announced the acquisition of Teralmmune, a privately held biotechnology firm focused on autoimmune disease therapies.
Baudax Bio shares jump on acquisition of TeraImmune
Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune diseases. TeraImmune has a cell therapy candidate to eliminate certain clotting factor inhibitors in patients with hemophilia A, a rare genetic bleeding disorder, Baudax said in a release.
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.
Baudax Bio Announces Date of Reconvened Annual Meeting
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the “Annual Meeting”) without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum.
Baudax Bio to Present at the Sidoti Virtual Investor Conference
MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place May 10-11, 2023.
Why Is Baudax Bio (BXRX) Stock Down 52% Today?
Baudax Bio (NASDAQ: BXRX ) stock is falling hard on Thursday after the pharmaceutical company announced a public stock offering. Baudax Bio reveals that it's selling 3,478,262 shares of BXRX stock in this offering.
Best Penny Stocks To Buy Now? 3 To Watch Today
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.
Why Is Baudax Bio (BXRX) Stock Up 50% Today?
What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000.
BXRX Financial details
BXRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 37.03 | 19.73 | 3.82K | |
| Net income per share | -11.36K | -2.7K | -5.82K | -431.36 | -246.53K | |
| Operating cash flow per share | -9.22K | -7.49K | -3.31K | -900.11 | -83.71K | |
| Free cash flow per share | -9.75K | -7.72K | -3.36K | -903.81 | -83.77K | |
| Cash per share | 0 | 2.66K | 2.28K | 290.31 | 15.84K | |
| Book value per share | -10.54K | -2.5K | -1.11K | 241.62 | -73.02K | |
| Tangible book value per share | -14.94K | -6.78K | -3.09K | -193.27 | -79.42K | |
| Share holders equity per share | -10.54K | -2.5K | -1.11K | 241.62 | -73.02K | |
| Interest debt per share | 0 | 115.75 | 836.43 | 197.92 | 84.91K | |
| Market cap | 63.54M | 64.7M | 18.83M | 16.78M | 1.06K | |
| Enterprise value | 63.54M | 47.73M | -1.74M | 9.42M | 1.86M | |
| P/E ratio | -0.86 | -3.59 | -0.24 | -0.71 | 0 | |
| Price to sales ratio | 0 | 0 | 38.19 | 15.54 | 0 | |
| POCF ratio | -1.06 | -1.29 | -0.43 | -0.34 | 0 | |
| PFCF ratio | -1.01 | -1.26 | -0.42 | -0.34 | 0 | |
| P/B Ratio | -0.93 | -3.87 | -1.27 | 1.27 | 0 | |
| PTB ratio | -0.93 | -3.87 | -1.27 | 1.27 | 0 | |
| EV to sales | 0 | 0 | -3.52 | 8.72 | 1.47 | |
| Enterprise value over EBITDA | -1.13 | -0.78 | 0.03 | -0.2 | -0.15 | |
| EV to operating cash flow | -1.06 | -0.95 | 0.04 | -0.19 | -0.07 | |
| EV to free cash flow | -1.01 | -0.93 | 0.04 | -0.19 | -0.07 | |
| Earnings yield | -1.16 | -0.28 | -4.12 | -1.41 | -77.52K | |
| Free cash flow yield | -0.99 | -0.8 | -2.37 | -2.95 | -26.34K | |
| Debt to equity | 0 | -0.05 | -0.66 | 0.65 | -0.29 | |
| Debt to assets | 0 | 0.01 | 0.14 | 0.16 | 0.71 | |
| Net debt to EBITDA | 0 | 0.28 | 0.39 | 0.15 | -0.15 | |
| Current ratio | 0.11 | 2.61 | 2.03 | 1.5 | 0.3 | |
| Interest coverage | 0 | 0 | -55.03 | -8.25 | -2.7 | |
| Income quality | 0.81 | 1.54 | 0.58 | 2.49 | 0.47 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 11.59 | |
| Research and developement to revenue | 0 | 0 | 18.43 | 2.89 | 3.06 | |
| Intangibles to total assets | 0.81 | 0.53 | 0.38 | 0.45 | 0.21 | |
| Capex to operating cash flow | 0.06 | 0.03 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -1.3 | -0.19 | -0.02 | |
| Capex to depreciation | -8.72 | -3.09 | -0.25 | -0.07 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 18.95 | 4.43 | 1.1 | |
| Graham number | 51.91K | 12.32K | 12.07K | 1.53K | 636.41K | |
| ROIC | 1.07 | 1.18 | 17.33 | -1.04 | 4.62 | |
| Return on tangible assets | -11.34 | -0.7 | -1.83 | -0.8 | -10.35 | |
| Graham Net | -15.94K | -7.97K | -3.88K | -388.26 | -86.64K | |
| Working capital | -20.27M | 12.42M | 18.59M | 7.85M | -15.11M | |
| Tangible asset value | -96.87M | -45.25M | -41.18M | -10.58M | -26.37M | |
| Net current asset value | -100.86M | -50.8M | -46.82M | -16.56M | -27.93M | |
| Invested capital | 0 | -0.05 | -0.66 | 0.65 | -0.29 | |
| Average receivables | 0 | 0 | 25.5K | 296.5K | 438.5K | |
| Average payables | 4.9M | 1.46M | 1.96M | 2.56M | 2.7M | |
| Average inventory | 0 | 0 | 1.49M | 3.99M | 2.5M | |
| Days sales outstanding | 0 | 0 | 37.76 | 183.18 | 96.36 | |
| Days payables outstanding | 0 | 0 | 769.83 | 219.15 | 204.5 | |
| Days of inventory on hand | 0 | 0 | 627.58 | 746.72 | 0 | |
| Receivables turnover | 0 | 0 | 9.67 | 1.99 | 3.79 | |
| Payables turnover | 0 | 0 | 0.47 | 1.67 | 1.78 | |
| Inventory turnover | 0 | 0 | 0.58 | 0.49 | 0 | |
| ROE | 1.08 | 1.08 | 5.24 | -1.79 | 3.38 | |
| Capex per share | -532.39 | -222.22 | -47.99 | -3.71 | -60.24 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.67 | 0.8 | 0.41 | -0.01 | 0.01 | |
| Net income per share | -45.06 | -100.42 | -14.43 | -3.27 | -1.51 | |
| Operating cash flow per share | -40.21 | -13.14 | -5.04 | -2.01 | -0.71 | |
| Free cash flow per share | -40.32 | -13.21 | -4.99 | -2.01 | -0.71 | |
| Cash per share | 29.02 | 19.08 | 7.01 | 1.64 | 0.29 | |
| Book value per share | 23.56 | -66.04 | -32.32 | -3.15 | -2.19 | |
| Tangible book value per share | -101.85 | -79.98 | -35.16 | -4.06 | -4.79 | |
| Share holders equity per share | 23.56 | -66.04 | -32.32 | -3.15 | -2.19 | |
| Interest debt per share | 63.28 | 180.28 | 10.72 | -3.82 | 1.8 | |
| Market cap | 6.07M | 2.91M | 2.39M | 3.95M | 5.72M | |
| Enterprise value | 9.57M | 5.35M | 4.25M | 7.58M | 13.07M | |
| P/E ratio | -0.19 | -0.02 | -0.06 | -0.13 | -0.19 | |
| Price to sales ratio | 20.23 | 12.23 | 7.69 | -282.03 | 190.52 | |
| POCF ratio | -0.84 | -0.75 | -0.63 | -0.85 | -1.66 | |
| PFCF ratio | -0.84 | -0.75 | -0.64 | -0.85 | -1.66 | |
| P/B Ratio | 1.43 | -0.15 | -0.1 | -0.54 | -0.54 | |
| PTB ratio | 1.43 | -0.15 | -0.1 | -0.54 | -0.54 | |
| EV to sales | 31.89 | 22.48 | 13.69 | -541.32 | 435.69 | |
| Enterprise value over EBITDA | -2.63 | 0.31 | -0.63 | -1.62 | -12.81 | |
| EV to operating cash flow | -1.33 | -1.38 | -1.12 | -1.62 | -3.79 | |
| EV to free cash flow | -1.32 | -1.37 | -1.13 | -1.62 | -3.79 | |
| Earnings yield | -1.33 | -10.21 | -4.54 | -1.92 | -1.29 | |
| Free cash flow yield | -1.19 | -1.34 | -1.57 | -1.18 | -0.6 | |
| Debt to equity | 2.06 | -0.41 | -0.29 | -1.02 | -0.82 | |
| Debt to assets | 0.21 | 0.46 | 0.71 | 1.05 | 0.41 | |
| Net debt to EBITDA | -0.96 | 0.14 | -0.28 | -0.77 | -7.21 | |
| Current ratio | 0.69 | 0.53 | 0.3 | 0.33 | 0.09 | |
| Interest coverage | -2.63 | 0.37 | -9.34 | 0.29 | 0 | |
| Income quality | 0.96 | 0.13 | 0.41 | 0.63 | 0.47 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 75.13 | |
| Research and developement to revenue | 3.04 | 2.71 | 3.35 | -208.36 | 59.3 | |
| Intangibles to total assets | 0.55 | 0.24 | 0.21 | 0.3 | 0.6 | |
| Capex to operating cash flow | 0 | 0.01 | -0.01 | 0 | 0 | |
| Capex to revenue | -0.07 | -0.08 | 0.13 | 0 | 0 | |
| Capex to depreciation | -0.03 | -0.03 | 0.38 | 0 | 0 | |
| Stock based compensation to revenue | 1.12 | 1.32 | 0.74 | -13.64 | 6.6 | |
| Graham number | 154.55 | 386.26 | 102.44 | 15.22 | 8.62 | |
| ROIC | -0.58 | -1.47 | 0.59 | -40.16 | -10 | |
| Return on tangible assets | -0.44 | -2.22 | -1.37 | -1.54 | -0.86 | |
| Graham Net | -157.65 | -97.77 | -38.35 | -4.55 | -6.26 | |
| Working capital | -5.7M | -10.01M | -15.11M | -8.26M | -18.6M | |
| Tangible asset value | -18.29M | -23.67M | -26.37M | -9.44M | -23.42M | |
| Net current asset value | -24.13M | -25.78M | -27.93M | -10.27M | -30.14M | |
| Invested capital | 2.06 | -0.41 | -0.29 | -1.02 | -0.82 | |
| Average receivables | 612K | 464.5K | 324K | 167.5K | 0 | |
| Average payables | 3.17M | 3.34M | 3.77M | 3.88M | 4.83M | |
| Average inventory | 5.23M | 4.87M | 2.24M | 0 | 0 | |
| Days sales outstanding | 184.8 | 118.36 | 97.26 | 0 | 0 | |
| Days payables outstanding | 763.88 | 268.88 | 73.75 | 852.67 | 5.04K | |
| Days of inventory on hand | 1.31K | 333.55 | 0 | 0 | 0 | |
| Receivables turnover | 0.49 | 0.76 | 0.93 | 0 | 0 | |
| Payables turnover | 0.12 | 0.33 | 1.22 | 0.11 | 0.02 | |
| Inventory turnover | 0.07 | 0.27 | 0 | 0 | 0 | |
| ROE | -1.91 | 1.52 | 0.45 | 1.04 | 0.69 | |
| Capex per share | -0.11 | -0.07 | 0.05 | 0 | 0 |
BXRX Frequently Asked Questions
What is Baudax Bio, Inc. stock symbol ?
Baudax Bio, Inc. is a US stock , located in Malvern of Pa and trading under the symbol BXRX
What is Baudax Bio, Inc. stock quote today ?
Baudax Bio, Inc. stock price is $0.303 today.
Is Baudax Bio, Inc. stock public?
Yes, Baudax Bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.14M
- Market Capitalization 3.17M
- Employee 9
- CEO Dr. Geraldine A. Henwood Ph.D.
- Headquarters Malvern,PA,US
- IPO Date 2019-11-14
-
Website
https://www.baudaxbio.com 
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
